Combined MEK and BCL-2/X(L) inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness

Most patients with late stage high-grade serous ovarian cancer (HGSOC) initially respond to chemotherapy but inevitably relapse and develop resistance, highlighting the need for novel therapies to improve patient outcomes. The MEK/ERK pathway is activated in a large subset of HGSOC making it an attr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Iavarone, Claudia, Zervantonakis, Ioannis K., Selfors, Laura M., Palakurthi, Sangeetha, Liu, Joyce F., Drapkin, Ronny, Matulonis, Ursula A., Hallberg, Dorothy, Velculescu, Victor E., Leverson, Joel D., Sampath, Deepak, Mills, Gordon B., Brugge, Joan S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6399746/
https://ncbi.nlm.nih.gov/pubmed/30679390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0413
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados